Skip to main content

Table 1 Demographic data of the recipients and donors (n = 50)

From: The combination of MELD score and ICG liver testing predicts length of stay in the ICU and hospital mortality in liver transplant recipients

 

Recipient

Donor

Male (%)

37 (74%)

36 (72%)

Female (%)

13 (26%)

14 (28%)

Age (yrs)

51.3 ± 11.1 (16 - 67)

53.2 ± 17.2 (19 - 86)

BMI (kg/m2)

25.7 ± 4.73 (16.6 - 42.9)

24.3 ± 3.3 (16.0- 31.0)

MELD

21 ± 10.4 (6 - 40)

 

RRT before TPL (%)

8 (16%)

 

HRS before TPL (%)

17 (34%)

 

SAPS II

30 ± 19 (0 - 91)

 

Creatinine (μmol/l)

121 ± 117 (40 - 814)

 

Hematocrit (%)

31.4 ± 7.6 (18.8 - 49.6)

 

Platelets (103/μl)

106 ± 65 (33 - 324)

 

INR

1.5 ± 0.6 (0.9 - 4.3)

 

Bilirubin (μmol/l)

148 ± 198 (5 - 875)

 

Etiology of liver disease

  

 HCV (%)

17 (34%)

 

 HBV (%)

3 (6%)

 

 HCC (%)

10 (20%)

 

 Alcoholic liver cirrhosis (%)

6 (12%)

 

 Cholangiocarcinoma (%)

2 (4%)

 

 Others1 (%)

12 (24%)

 

Cadaveric Donor (%)

 

44 (88%)

Living Donor (%)

 

6 (12%)

Extended donor graft criteria (%)

 

16 (32%)

  1. Data expressed as mean ± standard deviation (range). Abbreviations: BMI, body mass index; RRT, renal replacement therapy; TPL, transplantation; HRS, hepato-renal syndrome; SAPS, simplified acute physiology score; INR, international normalized ratio; HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma. Footnote: 1) encompasses primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis liver cirrhosis, Morbus Wilson, alpha-1-antitrypsin-defiency, acute liver failure, cryptogenic liver cirrhosis, Morbus Osler, polycyclic liver disease, recurrent intrahepatic cholestasis, vanishing bile duct syndrome, haemangioendothelioma.